Sign up USA
Proactive Investors - Run By Investors For Investors

Abbvie shares rising in New York on eczema drug news

The news led to a fall in rival Regeneron (NASDAQ:REGN), which shed over 5.6%
Abbvie shares rising in New York on eczema drug news
eczema is a skin condition

US drugs giant Abbvie (NYSE:ABBV) gained 6% in New York on news of its drug upadacitinib, which has met a mid-stage study goal.

The candidate is used to treat adults with moderate-to-severe eczema - a chronic skin disorder. 

The news in turn led to a fall in US rival Regeneron (NASDAQ:REGN), which shed over 5.6% to stand at $472 each.

Regeneron's drug Dupixent was approved by the US Food and Drug Administration in March this year.

Broker Jefferies said in a note that AbbVie’s mid-stage trial data for its drug, upadacitinib, seemed comparable to Dupixent’s late-stage data and the two treatments could be competitors.

Abbvie reportedly is planning a late-stage study for upadacitinib next year, and shares rose nearly 3% in late morning trading.

Abbvie shares were up 6.19% at the time of writing at $81.82 each.

View full ABBV profile View Profile

Abbvie Timeline

Related Articles

picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
Harley Street sign
December 07 2017
The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre
couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use